Disclosed is the use of 5-(4-(2-(3-methoxyphenyl)-2-oxoethoxy)benzyl)thiazolidine-2,4-dione represented by structural formula depicted herein for the manufacture of a medicament for treating hypertension, wherein the medicament may further comprises a diuretic, statin, angiotension II receptor blocker, a renin inhibitor, a beta adrenergic blocker, or any combination thereof； a glucocorticoid agonist； the medicament is also suitable for treating an inflammatory disease selected from rheumatoid arthritis, lupus, myasthenia gravis, muscular dystrophy, vasculitis, Chronic Obstructive Pulmonary Disease, inflammatory bowel disease, multiple schlerosis, acute allergic reactions, and transplant rejections, and may further comprise a glucocorticoid agonist is selected from cortisone, hydrocortisone, predisone, prednisolone, methylprednisolone, betamethasone, and triameclinolone.
